The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor

International Journal of Cancer

Volumn 135, Issue 4, 2014, Pages 1002-1006

  Suda, Kenichi ^a   Mizuuchi, Hiroshi ^a   Sato, Katsuaki ^a   Takemoto, Toshiki ^a   Iwasaki, Takuya ^a   Mitsudomi, Tetsuya ^a  

^a KINKI UNIVERSITY   (Japan)

Author keywords

AXL; EGFR TKI resistance; IGF1R; in vitro model

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; SOMATOMEDIN C RECEPTOR;

ARTICLE; CANCER CELL; CANCER RESISTANCE; CONTROLLED STUDY; DRUG EXPOSURE; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; WILD TYPE;

AXL; EGFR-TKI RESISTANCE; IGF1R; IN VITRO MODEL;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MUTATION; PHOSPHORYLATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; RNA, SMALL INTERFERING;

EID: 84902299673     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28737     Document Type: Article

References (22)

1. Takano T, Fukui T, Ohe Y, et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol 2008; 26: 5589-95.
2. Suda K, Ito S, Mizuuchi H, et al. EGFR tyrosine kinase inhibitors prolong overall survival in EGFR mutated non-small-cell lung cancer patients with postsurgical recurrence. J Cancer Res Updates 2012; 1: 102-7.
3. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010; 11: 521-9.
4. Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 26: 4268-75.
5. Yonesaka K, Zejnullahu K, Lindeman N, et al. Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers. Clin Cancer Res 2008; 14: 6963-73.
6. Piperdi B, Ling YH, Perez-Soler R,. Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small cell lung cancer cell lines. J Thorac Oncol 2007; 2: 715-21.
7. Thomson S, Petti F, Sujka-Kwok I, et al. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy. Clin Exp Metastasis 2008; 25: 843-54.
8. Ling YH, Li T, Perez-Soler R, et al. Activation of ER stress and inhibition of EGFR N-glycosylation by tunicamycin enhances susceptibility of human non-small cell lung cancer cells to erlotinib. Cancer Chemother Pharmacol 2009; 64: 539-48.
9. Petty WJ, Voelzke WR, Urbanic JJ, et al. High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancer. Lung Cancer 2011; 74: 384-91.
10. Suda K, Murakami I, Katayama T, et al. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res 2010; 16: 5489-98.
11. Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004; 64: 8919-23.
12. Suda K, Tomizawa K, Fujii M, et al. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol 2011; 6: 1152-61.
13. Garcia-Echeverria C, Pearson MA, Marti A, et al. In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004; 5: 231-9.
14. Selvaggi G, Novello S, Torri V, et al. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol 2004; 15: 28-32.
15. Suda K, Mizuuchi H, Maehara Y, et al. Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation-diversity, ductility, and destiny. Cancer Metastasis Rev 2012; 31: 807-14.
16. Rho JK, Choi YJ, Lee JK, et al. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer 2009; 63: 219-26.
17. Krysan K, Cui X, Gardner BK, et al. Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer. Am J Transl Res 2013; 5: 481-96.
18. Zhang Z, Lee JC, Lin L, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 2012; 44: 852-60.
19. Paccez JD, Vogelsang M, Parker MI, et al. The receptor tyrosine kinase Axl in cancer: Biological functions and therapeutic implications. Int J Cancer 2014; 134: 1024-33.
20. Guix M, Faber AC, Wang SE, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008; 118: 2609-19.
21. Cortot AB, Repellin CE, Shimamura T, et al. Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway. Cancer Res 2013; 73: 834-43.
22. Vazquez-Martin A, Cufi S, Oliveras-Ferraros C, et al. IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations. Sci Rep 2013; 3: 2560.